top left corner image top right corner image
 

Using immunology to fight cancer

Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases. Scancell’s first cancer vaccine SCIB1 is being developed for the treatment of melanoma and is in Phase I clinical trials.


 
Banner

ImmunoBody® Technology

Generating high avidity T-cell responses for more effective immunotherapy.

More on ImmunoBody® Technology

Share price

Scancell Holdings plc is a PLUS-quoted Company.

View share price information